

REMARKS

Claims 44-47, 51, 52, 56, 57, 60-64, 66, 68, 70, 72-75, 77, 79-82, and 92-101 are pending; claims 56, 57, 60-64, 66, 68, 70, 77, 80-82, and 92-99 are withdrawn from consideration as being directed to non-elected inventions; claims 44-47, 51, 52, 72-75, 79, and 101 are allowed; and claim 100 is objected to. In addition, the specification is objected to for failing to comply with the sequence rules set forth in 37 C.F.R. §§ 1.821-1.825. Applicants address these objections as follows.

The Office objects to the specification for not including sequence identifiers for all sequences disclosed therein. The specification has been amended to include sequence identifiers for the sequences shown in Figures 1A, 7A, 8A, 9A, 11A, and 15A. Applicants submit that all amino acid and nucleic acid sequences disclosed in the specification have now been assigned a unique sequence identification number. A new sequence listing which includes all sequences set forth in the specification is being submitted with the concurrently filed Statement under 37 C.F.R. §§ 1.821-1.825.

Claim 100 is objected to as being dependent upon non-elected claims and therefore non-elected inventions. Claim 100 has been amended to be directed to the elected invention. In view of this amendment, the objection to claim 100 should be withdrawn.


In addition, withdrawn claims 56, 57, 60-64, 66, 68, 70, 77, 80-82, and 92-99 have been canceled.

CONCLUSION

Applicants submit that the application is now in condition for allowance, and this action is hereby respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 July 2005



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045